Protox Therapeutics Inc. today announced that it has completed dosing of all four cohorts of patients in its previously announced transrectal study of PRX302 for the treatment of benign prostatic hyperplasia (BPH).
“We are very pleased to have completed the enrollment of this study according to the timeline, which is an important milestone advancing the PRX302 development program.” said Dr. Lars Ekman, Executive Chairman and President of Protox.
The primary objective of this study is to gather safety information regarding the transrectal route of administration for the intraprostatic injection of PRX302. There were no safety issues identified by the Independent Data Monitoring Committee based on data for all patients through at least the first 15 days after dosing. Patients will continue to be followed for up to 12 months with the 3 month safety data on all patients expected in Q3 2012.